
|Videos|July 25, 2023
SUNSHINE and SUNRISE Trials in HS
Author(s)Renata Block, MMS, PA-C
An expert in dermatology reviews the phase 3 SUNSHINE and SUNRISE trials evaluating the use of secukinumab given in 2-week intervals in patients with HS and shares clinical pearls for managing the condition.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
2
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
3
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
4
What Are the Side Effects of Hair and Skin Supplements in Dermatology? With Rajani Katta, MD
5


















































































